Table 3.

Factors predictive for clinical benefit (SD ≥ 6 months/PR/CR) with systemic therapy among patients with carcinomas of unknown primary (N = 55). CI, confidence interval; OR, odds ratio.

Characteristics	Treatment response (SD ≥ 6 months/PR/CR) (N = 55) a
	Univariate		Multivariate
	Rate (N)	P‐value	OR (95%CI)	P‐value
Age, years b
≥ 64 [N = 28] vs. < 64 [N = 27]	43% (12/28) vs. 30% (8/27)	0.40	—	—
Sex
Female [N = 30] vs. male [N = 25]	40% (12/30) vs. 32% (8/25)	0.59	—	—
Histology
Adenocarcinoma [N = 29] vs. not [N = 26]	45% (13/29) vs. 27% (7/26)	0.26	—	—
Treatment
Administered as 1st line [N = 36] vs. ≥ 2nd line [N = 19]	36% (13/36) vs. 37% (7/19)	> 0.99	—	—
≥ 2 drugs [N = 45] vs. single drug [N = 10]	40% (18/45) vs. 20% (2/10)	0.30	—	—
Matched [N = 34] vs. unmatched [N = 21]	44% (15/34) vs. 34% (5/21)	0.16	—	—
Matching Score > 50% [N = 14] vs. ≤ 50 [N = 41] c	71% (10/14) vs. 24% (10/41)	0.003	6.67 (1.30–33.3)	0.022
Immunotherapy based [N = 18] vs. other [N = 37] d	56% (10/18) vs. 27% (10/37)	0.043	1.32 (0.29–5.88)	0.73

^a Excluded 6 patients who had ongoing SD less than 6 months at the time of data cut‐off. Additionally, one patient was not evaluable for response assessment.

^b Age at treatment initiation. Dichotomized by the median value.

^c Low Matching Score group includes 21 patients with Matching Score = 0 (unmatched) and 20 patients with Matching Score of 1 to 50.

^d N = 37 patients received non‐immunotherapy‐based therapies.